As a new drug, biotechnology, or medical device product approaches market launch, its manufacturer must possess a clear, in-depth understanding of the public and private reimbursement environment that the product will face.
As the leader in developing solutions for complex health policy and reimbursement issues facing manufacturers, PAREXEL's Health Policy and Strategic Reimbursement Team provides our industry clients with a range of services to remove barriers to product acceptance, further appropriate patient access, and demonstrate a product's value. We also distill health policy developments into their essential elements and provide strategic recommendations to our clients on how broad healthcare issues will impact the industry
At PAREXEL we interact with key legislators, senior healthcare regulators, national association executives, and other public policy leaders to guide our clients through the complex and ever-changing healthcare landscape. Additionally, we work closely with PAREXEL's co-located Reimbursement HELPlines, Patient Assistance Programs, and Phase IV Program Coordinating Centers to provide our clients a single point of contact for strategic health policy and reimbursement solutions.
Our Reimbursement and Market Access services include:
